Taysha Gene Therapies Pre-Tax Profit Margin 2020-2025 | TSHA
Taysha Gene Therapies pre-tax profit margin from 2020 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Taysha Gene Therapies Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2025-03-31 |
$0.01B |
$-0.09B |
-1257.14% |
| 2024-12-31 |
$0.01B |
$-0.09B |
-1125.00% |
| 2024-09-30 |
$0.01B |
$-0.02B |
-230.00% |
| 2024-06-30 |
$0.01B |
$-0.11B |
-876.92% |
| 2024-03-31 |
$0.01B |
$-0.12B |
-842.86% |
| 2023-12-31 |
$0.02B |
$-0.11B |
-700.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.580B |
$0.008B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
